Latest Press Releases

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

December 18, 2023

Read More at Our Investor Site



Receive Email Alerts

Media Contact

Melissa Downs

Senior Director, Corporate Communications
646-975-2533

media@lantheus.com

Investors

Mark Kinarney

Vice President, Investor Relations
978-671-8842

ir@lantheus.com